Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | C1S | P09871 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29177324 | 0.86 | MEN1 (0.44) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| SCHEMBL8999515 | 0.86 | KMT2A (0.44) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| SCHEMBL28362239 | 0.86 | MEN1 (0.44) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| Tromethamine SCHEMBL1645080 | 0.85 | MEN1 (0.40) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| SCHEMBL11463871 | 0.82 | RXRB (0.41) | MEN1KMT2AMAPTTHRBTDP1 | |
| SCHEMBL26090155 | 0.81 | MGLL (0.45) | MEN1KMT2AMAPTTHRBPARP10 | |
| SCHEMBL3829975 | 0.80 | MEN1 (0.48) | MEN1KMT2AMAPTTHRBALDH1A1 | |
| SCHEMBL9721680 | 0.79 | KMT2A (0.50) | MEN1KMT2AALDH1A1TSHRCYP3A4 | |
| SCHEMBL5700033 | 0.79 | KMT2A (0.73) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL22980920 | 0.78 | TPMT (0.48) | MEN1KMT2AMAPTTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118311186-A | Method for measuring Wu Pa tenib intermediate and enantiomer thereof by liquid chromatography | 山东百诺医药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-117630224-A | Method for separating and measuring non-neridrone enantiomer by HPLC | 安徽联创生物医药股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-113680336-B | Cellulose coated spherical covalent organic framework chiral stationary phase and application | 华南师范大学 | 2024-01-30 | — | — | CN | claimed |
| CN-116609445-A | Acyclic nucleoside phosphonate compound and preparation method, analysis method and application thereof | 上海医药工业研究院有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-114264762-B | High performance liquid chromatography separation detection method for key intermediate enantiomer of tergolian praziquantel | 上海柏狮生物科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-115963217-A | Method for detecting imidapril intermediate and impurities | 北京阳光诺和药物研究股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115825284-A | Method for separating rivaroxaban intermediate and impurities thereof and detecting content of each component | 重庆华邦制药有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-115616104-A | Method for detecting enantiomer of dexmedetomidine hydrochloride injection | 山西远扬医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-115541733-A | Method for measuring protected amino acid enantiomer by reverse phase chromatography | 南京锐志生物医药有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115541731-A | Analysis method for protecting enantiomer of amino acid | 南京锐志生物医药有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-1944606-A2 | Method of analyzing optical purity of 1-Chloro-3, 5-Ditoluyl-2-Deoxy-L-Ribose using (S)-Tetrahydro-3-Furanol | Samchully Pharm. Co., Ltd. (KR) | 2008-07-16 | — | — | EP | claimed |
| US-20050065207-A1 | Method for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2005-03-24 | — | — | US | claimed |
| EP-0975560-A4 | CHIRAL SEPARATIONS OF AMINO ACIDS | CHIRAL TECHNOLOGIES INC (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1070076-A4 | CHIRAL SEPARATIONS OF PYRIMIDINES | CHIRAL TECHNOLOGIES INC (US) | 2002-05-29 | — | — | EP | claimed |
| EP-1070076-A1 | CHIRAL SEPARATIONS OF PYRIMIDINES | Chiral Technologies, Inc. (US) | 2001-01-24 | — | — | EP | claimed |
| US-6130353-A | Chiral separations of amino acids | CHIRAL TECHNOLOGIES, INC. (US) | 2000-10-10 | — | — | US | claimed |
| EP-0975560-A1 | CHIRAL SEPARATIONS OF AMINO ACIDS | Chiral Technologies, Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1999047531-A1 | CHIRAL SEPARATIONS OF PYRIMIDINES | CHIRAL TECHNOLOGIES, INC. (US) | 1999-09-23 | — | — | WO | claimed |
| WO-1998041489-A1 | CHIRAL SEPARATIONS OF AMINO ACIDS | CHIRAL TECHNOLOGIES, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| US-5811532-A | BOUND THROUGH A SPACER TO THE SURFACE HYDROXYL GROUPS OF A REFRACTORY INORGANIC OXIDE | UOP LLC (US) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065207-A1 | Method for the preparation of escitalopram | SLC6A4, GSK3B, GSK3A | MEN1 3845/4885KMT2A 2125/4885MAPT 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.